San Diego-primarily based Viking Therapeutics marked itself as a significant competitor in the weight loss drug market in February just after revealing promising info from the mid-stage trial of experimental drug VK2735, which suggested it rivaled—and outperformed—Novo and Lilly drugs when presented to be a weekly injection As well as in March